UCB To Exit Primary Care Market

Drugmaker UCB has announced that it is to exit the US's primary care market in March 2010 in order to accelerate its US transition to a purely specialty-focused biopharmaceutical company. The transition is part of the company's long-term strategy to become the patient-centric global biopharmaceutical leader focused on immunology and neurology, and is in line with the company's successful launches of its core products Cimzia (certolizumab pegol) and Vimpat (lacosamide) in the US. The drugmaker is currently awaiting US FDA approval for Neupro (rotigotine transdermal patch). BMI notes that UCB left the primary care markets in the majority of Western

To read the full article, please choose one of the following options: